Viewed: 175
Emailed: 0
PDF Downloaded: 1962
Full Text PDF Share on Facebook Share on Twitter
Original Article
Author Details :
Volume : 12, Issue : 3, Year : 2022
Article Page : 622-629
https://10.18231/j.pjms.2022.116
Abstract
Background: Heavy menstrual bleeding (HMB), is one of the most frequently encountered problem in the gynaecology OPD. It can significantly affect women’s quality of life and overburden health-care systems. The Levonorgestrel Releasing Intrauterine System (LNG-IUS) is a highly effective long-acting reversal contraceptive, also useful for controlling HMB and promoted by National Institute for Health and Care Excellence (NICE).
Materials and Methods: This prospective interventional study conducted upon 30 women, with heavy menstrual bleeding, of 30-50 years’ age, reporting in the outpatient department of a tertiary health care facility unit “between” January 2018 to June 2019. Women, who met inclusion and exclusion criteria were our study population. Data was collected during follow up at 1, 3 and 6 month and all the association were tested by mean, proportion and percentages. Chi-square test was used for comparing categorical result and p-value of less than 0.05 was considered as statistically significant. Calculation was made by using IBM SPSS 26 version of statistical software.
Results: Majority of women were from 40-45 years’ age group. Pictorial Blood Loss Assessment Chart (PBAC) score was calculated in 30 women who underwent LNG IUS insertion.There was significant reduction (p<0>
Conclusion: LNG IUS is effective and can be used as first line measure for treatment of HMB.
Keywords : Heavy menstrual bleeding, Levonorgestrel Releasing Intrauterine System, Pictorial Blood Loss Assessment Chart, Visual Analogue Scale
How to cite : Gupta A, Das S, Mahata R, Evaluation of effects of levonorgestrel releasing intrauterine system in heavy menstrual bleeding. Panacea J Med Sci 2022;12(3):622-629
Copyright © 2022 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)